IMUNON to Host R&D Day in New York City
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, is excited to announce its upcoming Research and Development (R&D) Day, which will take place at the esteemed Harvard Club in New York City. This event aims to delve into the promising potential of IL-12, a groundbreaking treatment strategy for advanced ovarian cancer. Attendees will have the opportunity to hear from leading experts in the field, along with prominent oncology figures who will share valuable insights from the ongoing OVATION 2 Study.
Insights on OVATION 2 Study
During the R&D Day, attendees will be presented with top-line data from the randomized Phase II OVATION 2 Study, findings that have made a significant impact within the clinical community. This research highlights a notable improvement in patient outcomes, showcasing an 11.1-month increase in median overall survival (OS) for the intent-to-treat population. These results reflect a remarkable 35% enhancement in survival rates for patients facing advanced stages of ovarian cancer.
Engaging with Experts
A key feature of the R&D Day will be discussions led by thought leaders in ovarian cancer and principal investigators from the Phase 2 OVATION 2 Study of IMNN-001. Together, they will examine the study's results and discuss how this data will influence the upcoming Phase 3 registration study. Participants will also gain insights into the strategic role that IMNN-001 could play in improving treatment protocols for patients with advanced ovarian cancer.
Networking Opportunities
Beyond the informative presentations, the event underscores the importance of in-person attendance as a vital chance for networking and direct engagement with the organization’s management and speakers. For those who cannot attend in person, virtual participation will be available, ensuring that everyone interested can access essential information.
About IMUNON and Its Innovative Approach
IMUNON is committed to advancing a variety of innovative treatments that harness the body’s immune system to promote safe, effective, and long-lasting responses against various human diseases. This unique approach sets IMUNON apart from conventional therapies. At the forefront of its initiatives is the development of non-viral DNA technology.
TheraPlas® and PlaCCine® Modalities
Among its groundbreaking efforts, IMUNON is developing TheraPlas®, which is designed for coding cytokines and other therapeutic proteins aimed at solid tumors where immunological methods show promise. Additionally, the company is working on PlaCCine®, intended for the delivery of DNA-coded viral antigens, with the goal of eliciting strong immunological responses to enhance patient outcomes.
Current Clinical Trials
The Company is advancing its lead clinical program, IMNN-001, a DNA-based immunotherapy specifically designed for treating localized advanced ovarian cancer. This innovative treatment has successfully completed Phase 2 clinical studies. IMNN-001 works by instructing the body to produce durable levels of powerful cancer-fighting molecules at the tumor site, including interleukin-12 and interferon gamma. In addition to its cancer treatments, IMUNON has launched a first-in-human study for its COVID-19 booster vaccine, known as IMNN-101.
Future Directions and Contact Information
IMUNON is dedicated to evolving its technologies and enhancing the application of plasmid DNA, all with the aim of better serving patients facing challenging medical conditions. For more information about their innovative therapies and ongoing studies, the company invites interested parties to visit their official website.
Contact Details
For direct inquiries, stakeholders can reach out to:
David Gaiero
IMUNON, Inc.
Phone: 978-376-6352
Email: dgaiero@imunon.com
Kim Sutton Golodetz
LHA Investor Relations
Phone: 212-838-3777
Email: kgolodetz@lhai.com
Frequently Asked Questions
What is the purpose of IMUNON's R&D Day?
The R&D Day aims to showcase the latest findings on ovarian cancer treatments, particularly focusing on the OVATION 2 Study and its implications for future research.
What are the key findings from the OVATION 2 Study?
The study revealed an 11.1-month increase in median survival for patients, indicating a 35% improvement for those with advanced ovarian cancer.
Who will be presenting at the R&D Day?
Experts in ovarian cancer, including thought leaders and principal investigators from significant studies, will present their insights and research findings.
Will there be an option for virtual attendance at the event?
Yes, IMUNON has arranged for virtual participation for those who are unable to attend in person.
How does IMNN-001 work?
IMNN-001 is a DNA-based immunotherapy that directs the body to produce cancer-fighting molecules right at the tumor site to combat advanced ovarian cancer.
